O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

Autor:	Athanasios Athanasiadis, Antonia Kalykaki, Nikos Androulakis, Ch. Kouroussis, D. Mavroudis, S. Tsousis, George Samonis, John Souglakos, Nikolaos Ziras, L. Vamvakas, V. Georgoulias, Kostas N. Syrigos, Aristidis Polyzos, S. Kakolyris
Rok vydání:	2006
Předmět:	Oncology medicine.medical_specialty FOLFOXIRI business.industry Colorectal cancer Subgroup analysis Hematology medicine.disease First line treatment Internal medicine medicine FOLFIRI business
Zdroj:	Critical Reviews in Oncology/Hematology. 60:S22-S23
ISSN:	1040-8428
DOI:	10.1016/s1040-8428(13)70069-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dd59cedaba0adc84a9b60ae167eabdee https://doi.org/10.1016/s1040-8428(13)70069-6 Zobrazit plný text záznamu Full Text from ScienceDirect